IN201721047406A - - Google Patents

Info

Publication number
IN201721047406A
IN201721047406A IN201721047406A IN201721047406A IN201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A
Authority
IN
India
Application number
IN201721047406A
Other languages
English (en)
Inventor
Sagar Baburao PATIL
Cheriyan AJI
Sandeep Dhondibhau POTE
Anirudha Bhagirath Kute
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Priority to IN201721047406A priority Critical patent/IN201721047406A/en
Priority to PCT/IB2018/060716 priority patent/WO2019130277A1/fr
Publication of IN201721047406A publication Critical patent/IN201721047406A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN201721047406A 2017-12-30 2018-12-29 IN201721047406A (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN201721047406A IN201721047406A (fr) 2017-12-30 2018-12-29
PCT/IB2018/060716 WO2019130277A1 (fr) 2017-12-30 2018-12-29 Formulations pharmaceutiques d'azilsartan médoxomil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721047406A IN201721047406A (fr) 2017-12-30 2018-12-29

Publications (1)

Publication Number Publication Date
IN201721047406A true IN201721047406A (fr) 2020-06-19

Family

ID=65278423

Family Applications (1)

Application Number Title Priority Date Filing Date
IN201721047406A IN201721047406A (fr) 2017-12-30 2018-12-29

Country Status (2)

Country Link
IN (1) IN201721047406A (fr)
WO (1) WO2019130277A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123592A1 (fr) * 2020-12-08 2022-06-16 Alkem Laboratories Ltd Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182778A1 (fr) * 2021-02-24 2022-09-01 Nostrum Pharmaceuticals, Llc Emballages pharmaceutiques et procédés de réduction de la formation de n-nitrosodiméthylamine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20090012132A1 (en) 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
NZ574954A (en) 2006-08-10 2011-11-25 Takeda Pharmaceutical Pharmaceutical composition comprising 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl} -1H-benzimidazole-7-carboxylic acid
ES2381507T3 (es) 2006-09-25 2012-05-28 Takeda Pharmaceutical Company Limited Envase medicinal
BRPI0809522A2 (pt) 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
KR20140030237A (ko) * 2011-05-23 2014-03-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤즈이미다졸 유도체를 함유하는 고체 약제학적 조성물
WO2014102628A1 (fr) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable comprenant de l'azilsartan médoxomil
US20160008328A1 (en) * 2014-07-11 2016-01-14 Cadila Healthcare Limited Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
CN105456210A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种高生物利用度的阿齐沙坦组合物
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123592A1 (fr) * 2020-12-08 2022-06-16 Alkem Laboratories Ltd Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci

Also Published As

Publication number Publication date
WO2019130277A1 (fr) 2019-07-04

Similar Documents

Publication Publication Date Title
BR122021024395A2 (fr)
BR122021023687A2 (fr)
BR122022003522A2 (fr)
BR122022025811B8 (fr)
BR122021000189A2 (fr)
IN201721047406A (fr)
BR112019008823A2 (fr)
BR112020006084A8 (fr)
BR122021014832A2 (fr)
BR202018014992U2 (fr)
BR112020008820A2 (fr)
BR202017025154U2 (fr)
BR102017023327A2 (fr)
BR202017021228U2 (fr)
BR202017020981U2 (fr)
BR202017017068U2 (fr)
BR202017016984U2 (fr)
BR202017016924U2 (fr)
BR202017012548U2 (fr)
BR202017011220U2 (fr)
BR202017010814U2 (fr)
BR202017010373U2 (fr)
BR202017009870U2 (fr)
BR202017006953U2 (fr)
BR202017004898U2 (fr)